U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06860633) titled 'Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod' on Feb. 28.
Brief Summary: This study plans to learn more about if the drug efgartigimod can be used in the hospital to treat exacerbations in participants with myasthenia gravis (MG). Efgartigimod has been approved by the FDA for ongoing (chronic) treatment of generalized MG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive but has not been studied in the treatment of worsening weakness requiring hospital admission (known as "exacerbation"). This investigation aims to see if using efgartigimod in this way improves symptoms and reco...